Quantifiable CYP2C Induction and Drug-Drug Interaction (DDI) Risk Assessment
Understanding the translation of in vitro positive CYP3A4 induction results to other pathways co-regulated with CYP3A— including other CYPs, UGTs, and transporters—is becoming a regulatory imperative. Current test methods using standard hepatocyte models however, fail to quantify the clinically observed induction potential of CYP2C enzymes (CYP2C8, CYP2C9, CYP2C19).
TruVivo provides more dynamic representation of CYP2C induction responses than conventional monoculture systems, which allows IVIVE and PBPK modeling to assess potential DDI risk.
- Induction risk assessment for CYP2C enzymes
- Clinical DDI prediction and quantitative IVIVE modeling
- Mechanistic studies of nuclear receptor activation pathways
- Early de-risking for co-inducer/inhibitor compounds
- Capture direction and magnitude of complex induction-inhibition interactions
Dive into the data and see how TruVivo provides:
- Quantifiable induction across multiple clinically relevant pathways
- Improved correlation between in vitro induction and clinical response
- Ability to characterize concurrent induction and inhibition effects
View Additional Resources
